ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Merck & Co. and Brazil’s Supera Farma Laboratorios have formed a joint venture to market pharmaceuticals and branded generics in Brazil. The partners will initially market approximately 30 products across multiple therapeutic areas. Meanwhile, Pfizer and Shanghai-based Hisun Pharmaceutical have advanced plans for a joint venture to commercialize off-patent drugs in China and other markets. Pfizer will own 49% of its joint venture with Hisun and invest $295 million in it. Merck will own 51% of its joint venture with Supera. Financial details of that deal were not disclosed.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter